AN2 Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ANTX Nasdaq 2830 www.an2therapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AN2 Therapeutics, Inc.

Favourable Signals For AN2 Therapeutics: Numerous Insiders Acquired Stock - Jan 19th, 2025 12:18 pm
Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor - Nov 21st, 2024 8:05 pm
AN2 Therapeutics to Participate at Upcoming Investor Conferences - Nov 14th, 2024 12:00 pm
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline - Nov 13th, 2024 9:00 pm
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria - Oct 17th, 2024 11:00 am
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Aug 28th, 2024 8:00 pm
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why - Aug 19th, 2024 2:29 pm
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan - Aug 16th, 2024 11:00 am
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights - Aug 13th, 2024 8:01 pm
Top Midday Decliners - Aug 9th, 2024 6:21 pm
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce - Aug 9th, 2024 4:15 pm
AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial - Aug 9th, 2024 1:33 pm
AN2 Therapeutics to Discontinue Clinical Study of Lung Disease Drug Candidate Epetraborole; Shares Plunge Pre-Bell - Aug 9th, 2024 12:52 pm
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease - Aug 8th, 2024 8:30 pm
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation - Jul 12th, 2024 11:30 am
Intuit initiated, Charter downgraded: Wall Street's top analyst calls - Jul 3rd, 2024 1:50 pm
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround - May 21st, 2024 1:35 pm
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights - May 14th, 2024 8:01 pm
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights - Mar 28th, 2024 8:10 pm
13 Best Falling Stocks To Buy Right Now - Feb 22nd, 2024 9:21 am